Joint Statement - Detection of MSX in Bedeque Bay, Prince Edward Island
OTTAWA, ON, July 13, 2024 /CNW/ - The Canadian Food Inspection Agency (CFIA) has confirmed the presence of multinuclear sphere X (MSX) caused by Haplosporidium nelsoni in wild oyster samples collected in Bedeque Bay, Prince Edward Island (PEI). While MSX prevents oysters from thriving, such as decreased rates of growth and increased oyster mortality, this disease poses no risk to human health, nor does it pose a risk to food safety.
To limit the spread of the disease, the CFIA, Fisheries and Oceans Canada (DFO) and the Province of PEI are working together with stakeholders and provincial/territorial partners to monitor the situation and take action as necessary.
These actions are part of the Government of Canada's One Health approach to prepare for, detect, and manage animal diseases. In addition to existing robust protective measures and increased animal surveillance measures, the CFIA, DFO and the Province continue to conduct tracing activities and testing of oysters to gain insight into the presence of MSX in the area. This testing is not conducted for food safety purposes.
Now that MSX has been detected, together the Government of Canada and Province of PEI are continuing the investigation and taking further response measures. At this time, these include:
applying movement controls in the Bedeque Bay area;
further investigating the potential source of the detection;
engaging scientists, producers and fish harvesters to continue to monitor mollusc health, including advising when significant decreased rates of growth or increased mortalities are observed; and
ensuring that information regarding detection and movement control information is available to producers.
Quick Facts
MSX is not a food safety concern.
Haplosporidium nelsoni causes multinuclear sphere X (MSX) disease in cultured and wild American oysters, specifically Crassostrea virginica.
Ongoing federal and provincial control and detection measures for MSX span the continuum from monitoring/surveillance and risk assessment, to laboratory capacity, updated guidance and communications, and science coordination.
In Canada, our animal disease surveillance network is supported by industry, the provinces and the federal government through a series of laboratories. There are measures in place for sampling and testing when there is any suspicion of animal disease.
Canada's National Aquatic Animal Health Program (NAAHP), co-delivered by the Canadian Food Inspection Agency (CFIA) and Fisheries and Oceans Canada (DFO), is responsible for preventing the introduction and/or spread of significant aquatic animal diseases of finfish, molluscs and crustaceans.
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National...
TransCode Therapeutics, Inc. , the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has agreed to sell an aggregate of 10,250,000 shares of its common stock and warrants to purchase up...
Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced on March 21st, 2025 its financial results for fiscal year 2024, reporting total revenue of RMB 2.7 billion, representing an 11.2%...
As the demand for surgical precision and faster patient recovery continues to grow, smart healthcare has achieved another major breakthrough. Since 2006, Chang Gung Memorial Hospital has pioneered the use of the Da Vinci Robotic Surgical Systems. By...
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the "Biologics - Global" category. It has also been...
CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab....